[{"id":"42d928bf-01a8-4f38-bc3e-dbcbf7fa205e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06161974","created_at":"2023-12-08T22:16:35.701Z","updated_at":"2025-02-25T13:41:56.353Z","phase":"Phase 2","brief_title":"Study of Olutasidenib and Temozolomide in HGG","source_id_and_acronym":"NCT06161974","lead_sponsor":"Rigel Pharmaceuticals","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Rezlidhia (olutasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 06/01/2029","primary_completion_date":" 06/01/2029","study_txt":" Completion: 06/01/2035","study_completion_date":" 06/01/2035","last_update_posted":"2025-02-21"},{"id":"70012bdf-9a68-4791-98f7-f3a645c2ba06","acronym":"","url":"https://clinicaltrials.gov/study/NCT04295759","created_at":"2021-01-18T20:50:32.592Z","updated_at":"2025-02-25T14:01:55.137Z","phase":"Phase 1","brief_title":"INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas","source_id_and_acronym":"NCT04295759","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" HER-2 • CD4 • ADAM10","pipe":"","alterations":" ","tags":["HER-2 • CD4 • ADAM10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aderbasib (INCB7839)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 07/27/2020","start_date":" 07/27/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2025-02-19"},{"id":"b568f31d-6b2b-46ca-879f-a90916765687","acronym":"","url":"https://clinicaltrials.gov/study/NCT05099003","created_at":"2021-10-29T14:53:11.674Z","updated_at":"2025-02-25T14:08:27.717Z","phase":"Phase 1/2","brief_title":"A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)","source_id_and_acronym":"NCT05099003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • IDH1","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • IDH1 mutation","tags":["BRAF • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Suspended","enrollment":" Enrollment 210","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-18"},{"id":"09faeec2-6d19-4e99-bfa8-ce9ad5372038","acronym":"","url":"https://clinicaltrials.gov/study/NCT05843253","created_at":"2023-05-06T15:04:11.203Z","updated_at":"2025-02-25T14:09:40.595Z","phase":"Phase 2","brief_title":"Study of Ribociclib and Everolimus in HGG and DIPG","source_id_and_acronym":"NCT05843253","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C","pipe":" | ","alterations":" PIK3CA mutation • CDKN2A deletion","tags":["PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CDKN2A deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/22/2024","start_date":" 08/22/2024","primary_txt":" Primary completion: 08/28/2028","primary_completion_date":" 08/28/2028","study_txt":" Completion: 08/28/2034","study_completion_date":" 08/28/2034","last_update_posted":"2025-02-17"},{"id":"64ec7fee-f0ad-4556-bc3c-857c74e02812","acronym":"","url":"https://clinicaltrials.gov/study/NCT04145115","created_at":"2021-07-05T17:26:08.613Z","updated_at":"2025-02-25T14:07:33.392Z","phase":"Phase 2","brief_title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","source_id_and_acronym":"NCT04145115","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type","tags":["EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 37","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2025-02-17"},{"id":"22e86fd8-4f8f-4456-992c-88f257edf9a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05345002","created_at":"2022-04-25T21:58:14.873Z","updated_at":"2025-02-25T14:41:19.773Z","phase":"Phase 2","brief_title":"All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma","source_id_and_acronym":"NCT05345002","lead_sponsor":"Stephen Bagley, MD, MSCE","biomarkers":" IDH1 • IDH2 • MGMT","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-14"},{"id":"1b444f14-d71f-4564-a2b3-eb610213a4f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04166409","created_at":"2021-01-18T20:19:50.287Z","updated_at":"2025-02-25T15:11:21.327Z","phase":"Phase 3","brief_title":"A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma","source_id_and_acronym":"NCT04166409","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • NF1","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Koselugo (selumetinib) • vincristine"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 01/31/2020","start_date":" 01/31/2020","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-02-13"},{"id":"c6ceadea-5216-44bc-b521-a84f4461c694","acronym":"","url":"https://clinicaltrials.gov/study/NCT03389802","created_at":"2021-01-18T16:43:48.401Z","updated_at":"2025-02-25T15:10:43.667Z","phase":"Phase 1","brief_title":"Phase I Study of APX005M in Pediatric Central Nervous System Tumors","source_id_and_acronym":"NCT03389802","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" TMB • TNFA • CXCL8 • CD4","pipe":"","alterations":" ","tags":["TMB • TNFA • CXCL8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sotigalimab (PYX-107)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-13"},{"id":"5f8b072a-82e7-4058-ac66-89f1f2f42c46","acronym":"","url":"https://clinicaltrials.gov/study/NCT04576117","created_at":"2021-01-18T21:50:45.604Z","updated_at":"2025-02-25T16:32:16.258Z","phase":"Phase 3","brief_title":"A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma","source_id_and_acronym":"NCT04576117","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • IDH1 • NF1","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • IDH1 mutation • IDH mutation + BRAF V600E","tags":["BRAF • IDH1 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • IDH1 mutation • IDH mutation + BRAF V600E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib) • vinblastine"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 02/16/2021","start_date":" 02/16/2021","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-02-07"},{"id":"597196ff-832d-47d8-abb2-6fd446401e06","acronym":"ACNS1721","url":"https://clinicaltrials.gov/study/NCT03581292","created_at":"2021-01-18T17:37:11.394Z","updated_at":"2025-02-25T16:52:13.824Z","phase":"Phase 2","brief_title":"Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations","source_id_and_acronym":"NCT03581292 - ACNS1721","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" IDH wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • veliparib (ABT-888)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 11/06/2018","start_date":" 11/06/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 10/16/2025","study_completion_date":" 10/16/2025","last_update_posted":"2025-02-04"},{"id":"bca1dafe-5b6f-43a8-b486-61c7b69a4e9d","acronym":"5G-RUBY","url":"https://clinicaltrials.gov/study/NCT06630260","created_at":"2025-02-25T19:12:02.371Z","updated_at":"2025-02-25T19:12:02.371Z","phase":"Phase 1/2","brief_title":"5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours","source_id_and_acronym":"NCT06630260 - 5G-RUBY","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 11/15/2024","start_date":" 11/15/2024","primary_txt":" Primary completion: 09/30/2029","primary_completion_date":" 09/30/2029","study_txt":" Completion: 09/30/2030","study_completion_date":" 09/30/2030","last_update_posted":"2025-01-22"},{"id":"254804cf-c50f-409d-b809-0f0a4043dc18","acronym":"CL1-95032-005","url":"https://clinicaltrials.gov/study/NCT05484622","created_at":"2022-08-02T12:55:57.680Z","updated_at":"2025-02-25T16:18:00.683Z","phase":"Phase 1","brief_title":"Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma","source_id_and_acronym":"NCT05484622 - CL1-95032-005","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • ATRX","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Voranigo (vorasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 01/20/2023","start_date":" 01/20/2023","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 08/30/2027","study_completion_date":" 08/30/2027","last_update_posted":"2025-01-14"},{"id":"eb5c9ee3-620e-48d0-bab8-f8f2914ede1d","acronym":"NRG-BN010","url":"https://clinicaltrials.gov/study/NCT04729959","created_at":"2021-03-09T19:55:01.650Z","updated_at":"2024-07-02T16:34:27.180Z","phase":"Phase 2","brief_title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","source_id_and_acronym":"NCT04729959 - NRG-BN010","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Actemra IV (tocilizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 03/11/2022","start_date":" 03/11/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-11"},{"id":"6e3accdd-5a43-478f-a02d-784bf9cd8ce5","acronym":"NCI-2018-00876","url":"https://clinicaltrials.gov/study/NCT03528642","created_at":"2021-01-18T17:22:22.349Z","updated_at":"2024-07-02T16:34:37.431Z","phase":"Phase 1","brief_title":"Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma","source_id_and_acronym":"NCT03528642 - NCI-2018-00876","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • telaglenastat (CB-839)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 12/05/2024","primary_completion_date":" 12/05/2024","study_txt":" Completion: 12/05/2024","study_completion_date":" 12/05/2024","last_update_posted":"2024-06-07"},{"id":"69c0c3d7-d12e-4846-a87b-98d5f38f2dcd","acronym":"SJDAWN","url":"https://clinicaltrials.gov/study/NCT03434262","created_at":"2021-01-18T16:56:26.116Z","updated_at":"2025-02-25T15:54:00.489Z","phase":"Phase 1","brief_title":"SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors","source_id_and_acronym":"NCT03434262 - SJDAWN","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • gemcitabine • Kisqali (ribociclib) • Odomzo (sonidegib) • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 03/05/2018","start_date":" 03/05/2018","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 05/24/2024","study_completion_date":" 05/24/2024","last_update_posted":"2024-05-31"},{"id":"87923196-97d9-4e54-a07f-3d2558fab429","acronym":"","url":"https://clinicaltrials.gov/study/NCT02101905","created_at":"2021-01-18T09:41:49.492Z","updated_at":"2024-07-02T16:35:07.246Z","phase":"Phase 1","brief_title":"Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma","source_id_and_acronym":"NCT02101905","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 03/13/2014","start_date":" 03/13/2014","primary_txt":" Primary completion: 10/19/2021","primary_completion_date":" 10/19/2021","study_txt":" Completion: 10/19/2024","study_completion_date":" 10/19/2024","last_update_posted":"2024-04-29"},{"id":"ea3578e9-dece-4f8e-8a45-a557cb4ab371","acronym":"","url":"https://clinicaltrials.gov/study/NCT02192359","created_at":"2021-01-18T10:14:16.362Z","updated_at":"2024-07-02T16:35:07.217Z","phase":"Phase 1","brief_title":"Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas","source_id_and_acronym":"NCT02192359","lead_sponsor":"City of Hope Medical Center","biomarkers":" UGT1A1","pipe":"","alterations":" ","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/07/2016","start_date":" 03/07/2016","primary_txt":" Primary completion: 02/21/2022","primary_completion_date":" 02/21/2022","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-04-29"},{"id":"9e89006d-b52b-45d1-b2b6-670282331015","acronym":"","url":"https://clinicaltrials.gov/study/NCT01089101","created_at":"2021-01-17T17:15:45.070Z","updated_at":"2024-07-02T16:35:07.463Z","phase":"Phase 1/2","brief_title":"Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma","source_id_and_acronym":"NCT01089101","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • KIAA1549-BRAF fusion • BRAF fusion","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KIAA1549-BRAF fusion • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 04/19/2010","start_date":" 04/19/2010","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-25"},{"id":"84233739-ed53-4cf9-9895-5c8bd3e952d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03043391","created_at":"2021-01-18T14:59:13.296Z","updated_at":"2024-07-02T16:35:10.938Z","phase":"Phase 1","brief_title":"Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children","source_id_and_acronym":"NCT03043391","lead_sponsor":"Istari Oncology, Inc.","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lerapolturev (PVS-RIPO)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 11/07/2017","start_date":" 11/07/2017","primary_txt":" Primary completion: 03/23/2022","primary_completion_date":" 03/23/2022","study_txt":" Completion: 03/23/2022","study_completion_date":" 03/23/2022","last_update_posted":"2024-04-08"},{"id":"3dd7c2f3-5edb-4afd-aab6-f0b5ef867dad","acronym":"","url":"https://clinicaltrials.gov/study/NCT03796273","created_at":"2021-01-18T18:46:15.719Z","updated_at":"2024-07-02T16:35:11.784Z","phase":"Phase 1","brief_title":"Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases","source_id_and_acronym":"NCT03796273","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" KDR • CD24 • POU5F1 • VEGFC","pipe":"","alterations":" ","tags":["KDR • CD24 • POU5F1 • VEGFC"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-04-03"},{"id":"f8142c0b-7e40-45b9-aed0-5a10b17b3a25","acronym":"FIRELIGHT-1","url":"https://clinicaltrials.gov/study/NCT04985604","created_at":"2023-06-26T16:09:30.280Z","updated_at":"2024-07-02T16:35:12.349Z","phase":"Phase 1/2","brief_title":"Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors","source_id_and_acronym":"NCT04985604 - FIRELIGHT-1","lead_sponsor":"Day One Biopharmaceuticals, Inc.","biomarkers":" BRAF • NF1 • RAF1","pipe":" | ","alterations":" BRAF fusion • RAF1 amplification","tags":["BRAF • NF1 • RAF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF fusion • RAF1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib) • pimasertib (AS703026)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 07/15/2021","start_date":" 07/15/2021","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-29"},{"id":"2a616249-11ac-4d5e-bcef-f68f308c0720","acronym":"","url":"https://clinicaltrials.gov/study/NCT06214689","created_at":"2024-01-19T19:20:28.219Z","updated_at":"2024-07-02T16:35:17.372Z","phase":"","brief_title":"IDH1 and OCT4 in High Grade Astrocytoma","source_id_and_acronym":"NCT06214689","lead_sponsor":"Assiut University","biomarkers":" IDH1 • POU5F1","pipe":"","alterations":" ","tags":["IDH1 • POU5F1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-02-28"},{"id":"9e7aadce-c10d-42e5-89cd-07b8fcf58f56","acronym":"","url":"https://clinicaltrials.gov/study/NCT03896568","created_at":"2021-01-18T19:11:27.737Z","updated_at":"2024-07-02T16:35:17.987Z","phase":"Phase 1","brief_title":"MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma","source_id_and_acronym":"NCT03896568","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IDH1","pipe":" | ","alterations":" IDH wild-type","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tasadenoturev (DNX-2401)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/12/2019","start_date":" 02/12/2019","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-02-23"},{"id":"26dcc42b-ad10-4971-bd48-90b2e6447b5b","acronym":"PLGG - MEKTRIC","url":"https://clinicaltrials.gov/study/NCT05180825","created_at":"2022-01-06T22:53:32.817Z","updated_at":"2024-07-02T16:35:18.783Z","phase":"Phase 2","brief_title":"Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy","source_id_and_acronym":"NCT05180825 - PLGG - MEKTRIC","lead_sponsor":"University Hospital, Strasbourg, France","biomarkers":" BRAF • IDH1 • NF1 • MYBL1","pipe":" | ","alterations":" IDH1 mutation","tags":["BRAF • IDH1 • NF1 • MYBL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • vinblastine"],"overall_status":"Recruiting","enrollment":" Enrollment 134","initiation":"Initiation: 05/05/2022","start_date":" 05/05/2022","primary_txt":" Primary completion: 11/01/2031","primary_completion_date":" 11/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-02-19"}]